Trials / Completed
CompletedNCT00252668
Study Evaluating the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis Subjects
An Open-Label, Multicentre, Extension Study of the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis Subjects
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 300 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open label extension of a previously completed double-blind, randomized study comparing etanercept and methotrexate in subjects with active rheumatoid arthritis. All subjects will receive combination treatment with etanercept and methotrexate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Etanercept | |
| DRUG | Methotrexate |
Timeline
- Start date
- 2004-06-01
- Completion
- 2005-09-01
- First posted
- 2005-11-11
- Last updated
- 2011-05-18
Source: ClinicalTrials.gov record NCT00252668. Inclusion in this directory is not an endorsement.